Automated and Closed Cell Therapy Processing Systems

Chapter Outlines

Chapter 2 is an executive summary of the key insights captured in our research. It offers a high-level view on the current state of the automated and closed cell therapy processing systems market and its likely evolution in the short-mid-term and long term.

Chapter 3 is an introductory chapter that presents a general overview of the cell and advanced therapies domain, along with details on the various types of products. It features a detailed discussion on the key challenges associated with currently adopted cell therapy manufacturing approaches. The chapter also highlights the role of automation in cell therapy manufacturing, providing details on the key advantages and challenges associated with such systems. Further, it features a discussion on the key growth drivers and roadblocks related to the use of such systems, as well as certain trends that the domain is expected to witness in the coming years.

Chapter 4 provides an overview of the automated and closed cell therapy processing systems landscape. It includes information on more than 60 automated and closed systems that are currently being used for processing the cell therapies. It features detailed information on the cell therapy processing step for which they are designed (apheresis, separation, expansion, harvest, fill / finish, cryopreservation and thawing), their key features (traceability, user-friendliness, configurability and scalability, process monitoring, touch-screen user interface, data management, integration with other systems and alert systems), product specifications (length, width, depth, height and weight), type of cells supported (stem cells and immune cells), type of cell culture (adherent and suspension), scale of operation (pre-clinical, clinical and commercial), application (research and therapeutic), end users (hospitals / medical centers / clinics, research institutes / academic institutes, laboratories, commercial organizations), key support services offered (product support, technical support, training, installation, qualification / validation, maintenance, regulatory support and others), regulatory certification / accreditations obtained (GMP / cGMP, GAMP, GCP, GTP / cGTP, IEC standards, ISO standards, 21 CFR Part 11 and other).

Chapter 5 presents a detailed competitiveness analysis of automated and closed cell therapy processing systems based on the supplier power and key product specifications. The analysis was designed to enable stakeholder companies to compare their existing capabilities within and beyond their respective peer groups and identify opportunities to achieve a competitive edge in the industry.

Chapter 6 presents detailed profiles of industry players that are currently offering automated and closed cell therapy processing systems, featuring an overview of the company, its financial information (if available), and a detailed description of the system(s) they offer. Each profile also includes a list of recent developments, highlighting the key achievements, partnership activity, and the likely strategies that may be adopted by these players to fuel growth, in the foreseen future.

Chapter 7 features an elaborate analysis of the various partnerships and collaborations that have been inked amongst players in this domain, during the period 2016-2020. It provides a brief description on the various types of partnership models adopted (including asset purchase agreement, distribution agreement, joint venture, merger / acquisition,  product commercialization agreement, product development agreement, product development and commercialization agreement, product evaluation agreement, product integration agreement, product utilization agreement, research agreement and others) by stakeholders in this domain. Further, it includes analyses based on the year of partnership, type of partnership model adopted, type of therapy, type of cell processing step, key automated and closed cell processing systems, partner’s focus area, most active players (in terms of number of partnerships signed), and geographical location of collaborators.

Chapter 8 highlights the recent initiatives undertaken by big pharma players in the automated and closed cell therapy processing systems domain.

Chapter 9 features a list of more than 300 cell therapy developers and manufacturers that are anticipated to partner with automated and closed cell therapy processing system providers and have been shortlisted on the basis of parameters, such as developer strength (which takes into account a company’s size and its experience in this field), company’s pipeline strength and maturity (based on the number of pipeline drugs and affiliated stage of development), type of culture used (adherent or suspension) and type of technology (automated systems or closed systems).

Chapter 10 presents a case study, highlighting the differences in cost associated with manufacturing of cell therapies using manual, partially automated and bespoke automated and closed systems, across various process operations.

Chapter 11 presents a detailed market forecast analysis, highlighting the likely growth of the automated and closed cell therapy processing systems market till the year 2030. In order to provide a detailed future outlook, our projections have been segmented on the basis of [A] different cell therapy processing steps (apheresis, separation, expansion, harvest, fill / finish, cryopreservation and thawing), [B] scale of operations (pre-clinical / clinical and commercial), [C] end users (hospitals / medical centers / clinics, research institutes / academic institutes, laboratories, commercial organizations), and [D] key geographical regions (North America, Europe, Asia-Pacific, Middle East and Latin America).

Chapter 12 is a collection of interview transcripts of the discussions held with key stakeholders in the industry. We have presented details of interviews held with Peter Molloy (Executive Vice President, Orgenesis) and Shimon Hassin (Chief Technology Officer, Orgenesis), and Jean Sebastien Parisse (Commercial Director, Aseptic Technologies).

Chapter 13 is a summary of the overall report. In this chapter, we have provided a list of key takeaways from the report, and expressed our independent opinion related to the research and analysis described in the previous chapters.

Chapter 14 is an appendix that contains tabulated data and numbers for all the figures provided in the report.

Chapter 15 is an appendix that provides the list of companies and organizations mentioned in the report.

Table Of Contents

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Context and Background
3.2. Cell Therapies
3.3. Cell Therapy Manufacturing
3.4. Key Challenges Associated with Manufacturing Cell Therapies
3.5. Overview of Automated and Closed Cell Processing Systems
3.5.1. Need for Automated and Closed Cell Processing in Cell Therapy Manufacturing
3.5.2. Advantages and Affiliated Challenges
3.6. Key Growth Drivers and Roadblocks
3.7. Recent Developments and Upcoming Trends

4. COMPETITIVE LANDSCAPE
4.1. Chapter Overview
4.2. Automated and Closed Cell Therapy Processing Systems: Overall Market Landscape
4.2.1. Analysis by Cell Processing Step
4.2.2. Analysis by Types of Cells 
4.2.3. Analysis by Type of Culture
4.2.4. Analysis by Scale of Operation
4.2.5. Analysis by Key Features
4.2.6. Analysis by Application Area
4.2.7. Analysis by Regulatory Certifications / Accreditations 
4.2.8. Analysis by End User

4.3. Automated and Closed Cell Therapy Processing Systems: Developer Landscape
4.3.1. Analysis by Year of Establishment
4.3.2. Analysis by Company Size 
4.3.3. Analysis by Type of Support Service(s) Offered 
4.3.4. Analysis by Location of Headquarters 

5. PRODUCT COMPETITIVENESS ANALYSIS
5.1. Chapter Overview
5.2. Assumptions / Key Parameters
5.3. Methodology
5.4. Product Competitiveness Analysis
5.4.1. Automated and Closed Cell Processing Systems for Apheresis
5.4.2. Automated and Closed Cell Processing Systems for Separation
5.4.3. Automated and Closed Cell Processing Systems for Expansion
5.4.4. Automated and Closed Cell Processing Systems for Harvest
5.4.5. Automated and Closed Cell Processing Systems for Fill Finish
5.4.6. Automated and Closed Cell Processing Systems for Cryopreservation
5.4.7. Automated and Closed Cell Processing Systems for Thawing

6. COMPANY PROFILES
6.1 Chapter Overview
6.2 Cytiva
6.2.1. Company Overview
6.2.2. Product Portfolio
6.2.3. Recent Developments and Future Outlook

6.3. Pall
6.3.1. Company Overview
6.3.2. Product Portfolio
6.3.3. Recent Developments and Future Outlook

6.4. Terumo BCT
6.4.1. Company Overview
6.4.2. Product Portfolio
6.4.3. Financial Information
6.4.4. Recent Developments and Future Outlook

6.5 ThermoGenesis
6.5.1. Company Overview
6.5.2. Product Portfolio
6.5.3. Financial Information
6.5.4. Recent Developments and Future Outlook

7. PARTNERSHIPS
7.1 Chapter Overview
7.2. Partnership Models
7.3. Automated and Closed Cell Therapy Processing Systems: Recent Partnerships
7.3.1. Analysis by Year of Partnership
7.3.2. Analysis by Type of Partnership
7.3.3. Analysis by Type of Therapy
7.3.4. Analysis by Cell Processing Step
7.3.5. Analysis by Type of Automated and Closed Cell Processing Systems
7.3.6. Analysis by Partner’s Focus Area
7.3.7. Most Active Players: Analysis by Number of Partnerships
7.3.8. Geographical Analysis
7.3.8.1. Country-Wise Distribution
7.3.8.2. Intercontinental and Intracontinental Agreements

8. BIG PHARMA INITIATIVES IN AUTOMATED AND CLOSED CELL THERAPY PROCESSING SYSTEMS DOMAIN
8.1. Chapter Overview
8.2. Initiatives Undertaken by Big Pharma Players
8.2.1. Initiatives Undertaken by AbbVie
8.2.2. Initiatives Undertaken by Bristol Myers Squibb
8.2.3. Initiatives Undertaken by Gilead Sciences
8.2.4. Initiatives Undertaken by GlaxoSmithKline
8.2.5. Initiatives Undertaken by Johnson & Johnson
8.2.6. Initiatives Undertaken by Novartis
8.2.7. Initiatives Undertaken by Roche
8.2.8. Initiatives Undertaken by Sanofi
8.2.9. Initiatives Undertaken by Takeda Pharmaceutical
8.2.10. Summary of Big Pharma Initiatives 

9. LIKELY PARTNER
9.1. Chapter Overview
9.2. Scope and Methodology
9.3. Automated and Closed Cell Therapy Processing Systems: Potential Strategic Partners for Cell Therapy Development
9.3.1. Dendritic Cell Therapy
9.3.2. Stem Cell Therapy
9.3.3. T-cell Therapy
9.3.4. Natural Killer Cell Therapy

9.4. Automated and Closed Cell Therapy Processing Systems: Potential Strategic Partners for Cell Therapy Manufacturing
9.4.1. Dendritic Cell Therapy
9.4.2. Stem Cell Therapy,
9.4.3. T-cell Therapy
9.4.4. Natural Killer Cell Therapy

10. CASE STUDY: COST BENEFIT ANALYSIS USING PARTIALLY AUTOMATED AND FULLY AUTOMATED SYSTEMS
10.1. Chapter Overview
10.2. Comparative Analysis of Manual, Partially Automated and Fully Automated Cell Processing Systems
10.3. Likely Cost Saving Potential for Kymriah®
10.4. Likely Cost Saving Potential for Yescarata®
10.5. Cost Saving Potential of Fully Automated Processing Systems: Regional Trends
10.6. Concluding Remarks

11. MARKET SIZING AND OPPORTUNITY ANALYSIS
11.1. Chapter Overview
11.2. Key Assumptions and Methodology
11.3. Overall Automated and Closed Cell Therapy Processing Systems Market, 2020-2030

11.3.1. Overall Automated and Closed Cell Therapy Processing Systems Market: Distribution by Cell Therapy Processing Step
11.3.1.1. Automated and Closed Cell Therapy Processing Systems Market for Apheresis, 2020-2030
11.3.1.2. Automated and Closed Cell Therapy Processing Systems Market for Separation, 2020-2030
11.3.1.3. Automated and Closed Cell Therapy Processing Systems Market for Expansion, 2020-2030
11.3.1.4. Automated and Closed Cell Therapy Processing Systems Market for Harvest, 2020-2030
11.3.1.5. Automated and Closed Cell Therapy Processing Systems Market for Fill / Finish, 2020-2030
11.3.1.6. Automated and Closed Cell Therapy Processing Systems Market for Cryopreservation, 2020-2030
11.3.1.7. Automated and Closed Cell Therapy Processing Systems Market for Thawing, 2020-2030

11.3.2. Automated and Closed Cell Therapy Processing Systems Market: Distribution by Scale of Operation
11.3.2.1. Automated and Closed Cell Therapy Processing Systems Market for Pre-clinical / Clinical Operations, 2020-2030
11.3.2.2. Automated and Closed Cell Therapy Processing Systems Market for Commercial Operations, 2020-2030

11.3.3. Automated and Closed Cell Therapy Processing Systems Market: Distribution by End User
11.3.3.1. Automated and Closed Cell Therapy Processing Systems Market for Hospitals / Medical Centers / Clinics / Research Institutes / Academic Institutes, 2020-2030
11.3.3.2. Automated and Closed Cell Therapy Processing Systems Market for Cell Therapy Manufacturers / Developers, 2020-2030

11.3.4. Automated and Closed Cell Therapy Processing Systems Market: Distribution by Key Geographic Regions
11.3.4.1. Automated and Closed Cell Therapy Processing Systems Market in North America, 2020-2030
11.3.4.2. Automated and Closed Cell Therapy Processing Systems Market in Europe, 2020-2030
11.3.4.3. Automated and Closed Cell Therapy Processing Systems Market in Asia-Pacific, 2020-2030
11.3.4.4. Automated and Closed Cell Therapy Processing Systems Market in Latin America (LATAM), 2020-2030
11.3.4.5. Automated and Closed Cell Therapy Processing Systems Market in Middle East North America (MENA), 2020-2030

12. CONCLUSION
12.1. Chapter Overview
12.2. Key Takeaways

13. INTERVIEW / SURVEY TRANSCRIPT(S)

14. APPENDIX 1: TABULATED DATA

15. APPENDIX 2: LIST OF COMPANIES AND ORGANISTIONS

List Of Figures

Figure 3.1. Key Steps Involved in Manufacturing of Cell Therapies
Figure 3.2. Key Considerations while Automating Cell Therapy Manufacturing Process
Figure 3.3. Role of Automated and Closed Systems across Each Cell Therapy Processing Step
Figure 3.4. Advantages offered by Automated and Closed Cell Processing Systems
Figure 3.5. Challenges Associated with Automated and Closed Cell Processing Systems
Figure 3.6. Growth Drivers and Roadblocks in the Automated and Closed Systems Market
Figure 4.1. Automated and Closed Cell Therapy Processing Systems: Distribution by Cell Processing Step
Figure 4.2. Automated and Closed Cell Therapy Processing Systems: Distribution by Types of Cells
Figure 4.3. Automated and Closed Cell Therapy Processing Systems: Distribution by Type of Culture
Figure 4.4. Automated and Closed Cell Therapy Processing Systems: Distribution by Scale of Operation
Figure 4.5. Automated and Closed Cell Therapy Processing Systems: Distribution by Key Features
Figure 4.6. Automated and Closed Cell Therapy Processing Systems: Distribution by Application Area
Figure 4.7. Automated and Closed Cell Therapy Processing Systems: Distribution by Regulatory Certifications / Accreditations
Figure 4.8. Automated and Closed Cell Therapy Processing Systems: Distribution by End Users
Figure 4.9. Automated and Closed Cell Therapy Processing System Providers: Distribution by Year of Establishment
Figure 4.10. Automated and Closed Cell Therapy Processing System Providers: Distribution by Company Size
Figure 4.11. Automated and Closed Cell Therapy Processing System Providers: Distribution by Type of Support Services Offered
Figure 4.12. Automated and Closed Cell Therapy Processing System Providers: Distribution by Geographical Location
Figure 4.13. Automated and Closed Cell Therapy Processing System Providers: Distribution by Geographical Location (Country-Wise)
Figure 4.14. Leading Developers: Distribution by Number of Automated and Closed Cell Therapy Processing Systems
Figure 5.1. Product Competitiveness Analysis: Automated and Closed Systems for Cell Apheresis
Figure 5.2. Product Competitiveness Analysis: Automated and Closed Systems for Cell Separation
Figure 5.3. Product Competitiveness Analysis: Automated and Closed Systems for Cell Expansion
Figure 5.4. Product Competitiveness Analysis: Automated and Closed Systems for Cell Harvesting
Figure 5.5. Product Competitiveness Analysis: Automated and Closed Systems for Fill Finish
Figure 5.6. Product Competitiveness Analysis: Automated and Closed Systems for Cryopreservation
Figure 5.7. Product Competitiveness Analysis: Automated and Closed Systems for Thawing
Figure 6.1. Terumo BCT: Annual Revenues, FY 2016 – FY 2020
Figure 6.2. ThermoGenesis: Annual Revenues, FY 2016 – FY 2020
Figure 7.1. Recent Partnerships: Cumulative Distribution by Year of Partnership
Figure 7.2. Recent Partnerships: Distribution by Type of Partnership Model Adopted
Figure 7.3. Recent Partnerships: Year-wise Trend by Type of Partnership Model Adopted
Figure 7.4. Recent Partnerships: Distribution by Type of Therapy
Figure 7.5. Recent Partnerships: Distribution by Type of Therapy and Type of Partnership Model Adopted
Figure 7.6. Recent Partnerships: Distribution by Cell Processing Step
Figure 7.7. Recent Partnerships: Distribution by Automated and Closed Cell Processing System
Figure 7.8. Recent Partnerships: Distribution by Type of Partner
Figure 7.9. Recent Partnerships: Distribution by Type of Cell Processing Step and Developer
Figure 7.10. Recent Partnerships: Most Active Players
Figure 7.11. Recent Partnerships: Country-Wise Distribution
Figure 7.12. Recent Partnerships: Intercontinental and Intracontinental Distribution
Figure 8.1. Big Pharma Initiatives Summary
Figure 10.1. Cost Saving Analysis: Comparative Analysis of Manual, Partially Automated and Fully Automated Processing Systems, 2020-2030
Figure 10.2. Cost Saving Potential of Fully Automated Processing Systems Based on Number of Patients
Figure 10.3. Cost Saving Potential of Fully Automated Processing Systems Across Different Regions
Figure 11.1. Overall Automated and Closed Cell Therapy Processing Systems Market, 2020-2030 (USD Million)
Figure 11.2. Automated and Closed Cell Therapy Processing Systems Market: Distribution by Cell Therapy Processing Step, 2020, 2025 and 2030 (USD Million)
Figure 11.3. Automated and Closed Cell Therapy Processing Systems Market: Share of Cell Apheresis Systems, 2020-2030 (USD Million)
Figure 11.4. Automated and Closed Cell Therapy Processing Systems Market: Share of Cell Separation Systems, 2020-2030 (USD Million)
Figure 11.5. Automated and Closed Cell Therapy Processing Systems Market: Share of Cell Expansion Systems, 2020-2030 (USD Million)
Figure 11.6. Automated and Closed Cell Therapy Processing Systems Market: Share of Cell Harvesting Systems, 2020-2030 (USD Million)
Figure 11.7. Automated and Closed Cell Therapy Processing Systems Market: Share of Fill Finish Systems, 2020-2030 (USD Million)
Figure 11.8. Automated and Closed Cell Therapy Processing Systems Market: Share of Cryopreservation Systems, 2020-2030 (USD Million)
Figure 11.9. Automated and Closed Cell Therapy Processing Systems Market: Share of Thawing Systems, 2020-2030 (USD Million)
Figure 11.10. Automated and Closed Cell Therapy Processing Systems Market: Distribution by Scale of Operation, 2020, 2025 and 2030 (USD Million)
Figure 11.11. Automated and Closed Cell Therapy Processing Systems Market: Share of Preclinical / Clinical Scale Operations, 2020-2030 (USD Million)
Figure 11.12. Automated and Closed Cell Therapy Processing Systems Market: Share of Commercial Operations, 2020-2030 (USD Million)
Figure 11.13. Automated and Closed Cell Therapy Processing Systems Market: Distribution by End User, 2020, 2025 and 2030 (USD Million)
Figure 11.14. Automated and Closed Cell Therapy Processing Systems Market: Share of Hospitals / Medical Centers / Clinics / Research Institutes / Academic Institutes, 2020-2030 (USD Million)
Figure 11.16. Automated and Closed Cell Therapy Processing Systems Market: Share of Commercial Organizations, 2020-2030 (USD Million)
Figure 11.17. Automated and Closed Cell Therapy Processing Systems Market: Distribution by Key Geographical Regions, 2020, 2025 and 2030 (USD Million)
Figure 11.18. Automated and Closed Cell Therapy Processing Systems Market: Share of North America, 2020-2030 (USD Million)
Figure 11.19. Automated and Closed Cell Therapy Processing Systems Market: Share of Europe, 2020-2030 (USD Million)
Figure 11.20. Automated and Closed Cell Therapy Processing Systems Market: Share of Asia-Pacific, 2020-2030 (USD Million)
Figure 11.21. Automated and Closed Cell Therapy Processing Systems Market: Share of LATAM, 2020-2030 (USD Million)
Figure 11.22. Automated and Closed Cell Therapy Processing Systems Market: Share of MENA, 2020-2030 (USD Million)

List Of Tables

Table 3.1. Cell and Advanced Therapies: Key Applications
Table 3.2. Assessment of Key Cell Therapy Manufacturing Steps
Table 4.1. List of Automated and Closed Cell Therapy Processing Systems: Information on Cell Processing Step
Table 4.2. List of Automated and Closed Cell Therapy Processing Systems: Information on Types of Cells
Table 4.3. List of Automated and Closed Cell Therapy Processing Systems: Information on Type of Culture
Table 4.4. List of Automated and Closed Cell Therapy Processing Systems: Information on Scale of Operation
Table 4.5. List of Automated and Closed Cell Therapy Processing Systems: Information on Key Features
Table 4.6. List of Automated and Closed Cell Therapy Processing Systems: Information on Application Area
Table 4.7. List of Automated and Closed Cell Therapy Processing Systems: Information on Regulatory Certifications / Accreditations Obtained
Table 4.8. List of Automated and Closed Cell Therapy Processing Systems: Information on End Users
Table 4.9. List of Automated and Closed Cell Therapy Processing System Providers
Table 4.10. List of Automated and Closed Cell Therapy Processing System Providers: Information on Type of Support Service(s) Offered
Table 6.1. Cytiva: Key Highlights
Table 6.2. Cytiva: Product Portfolio
Table 6.3. Pall: Key Highlights
Table 6.4. Pall: Product Portfolio
Table 6.5. Terumo BCT: Key Highlights
Table 6.6. Terumo BCT: Product Portfolio
Table 6.7. Terumo BCT: Recent Developments and Future Outlook
Table 6.8. ThermoGenesis: Key Highlights
Table 6.9. ThermoGenesis: Product Portfolio
Table 6.10. ThermoGenesis: Recent Developments and Future Outlook
Table 7.1. Automated and Closed Cell Processing Systems: List of Partnerships, 2016-2020
Table 8.1. Automated and Closed Cell Processing Systems: List of Big Pharma Players
Table 9.1. Likely Partners for Automated and Closed Cell Therapy Processing System Providers: Dendritic Cell Therapy Developers
Table 9.2. Likely Partners for Automated and Closed Cell Therapy Processing System Providers: Stem Cell Therapy Developers
Table 9.3. Likely Partners for Automated and Closed Cell Therapy Processing System Providers: T-cell Therapy Developers
Table 9.4. Likely Partners for Automated and Closed Cell Therapy Processing System Providers: Natural Killer Cell Therapy Developers
Table 9.5. Likely Partners for Automated and Closed Cell Therapy Processing System Providers: Dendritic Cell Therapy Manufacturers
Table 9.6. Likely Partners for Automated and Closed Cell Therapy Processing System Providers: Stem Cell Therapy Manufacturers
Table 9.7. Likely Partners for Automated and Closed Cell Therapy Processing System Providers: T-cell Therapy Manufacturers
Table 9.8. Likely Partners for Automated and Closed Cell Therapy Processing System Providers: Natural Killer Cell Therapy Manufacturers
Table 10.1. Comparative Analysis of Manual, Partially Automated and Fully Automated Cell Processing Systems, 2020-2030
Table 10.2. Cost Saving Potential of Fully Automated Systems
Table 14.1. Automated and Closed Cell Therapy Processing Systems: Distribution by Cell Processing Step
Table 14.2. Automated and Closed Cell Therapy Processing Systems: Distribution by Types of Cells
Table 14.3. Automated and Closed Cell Therapy Processing Systems: Distribution by Type of Culture
Table 14.4. Automated and Closed Cell Therapy Processing Systems: Distribution by Scale of Operation
Table 14.5. Automated and Closed Cell Therapy Processing Systems: Distribution by Key Features
Table 14.6. Automated and Closed Cell Therapy Processing Systems: Distribution by Application Area
Table 14.7. Automated and Closed Cell Therapy Processing Systems: Distribution by Regulatory Certifications / Accreditations
Table 14.8. Automated and Closed Cell Therapy Processing Systems: Distribution by End Users
Table 14.9. Automated and Closed Cell Therapy Processing System Providers: Distribution Year of Establishment
Table 14.10. Automated and Closed Cell Therapy Processing System Providers: Distribution by Company Size
Table 14.11. Automated and Closed Cell Therapy Processing System Providers: Distribution by Type of Support Services Offered
Table 14.12. Automated and Closed Cell Therapy Processing System Providers: Distribution by Geographical Location
Table 14.13. Automated and Closed Cell Therapy Processing System Providers: Distribution by Geographical Location (Country-Wise)
Table 14.14. Leading Developers: Distribution by Number of Automated and Closed Cell Therapy Processing Systems
Table 14.15. Terumo BCT: Annual Revenues, FY 2016-FY 2020
Table 14.16. ThermoGenesis: Annual Revenues, FY 2016 – FY 2020
Table 14.17. Recent Partnerships: Cumulative Distribution by Year of Partnership
Table 14.18. Recent Partnerships: Distribution by Type of Partnership Model Adopted
Table 14.19. Recent Partnerships: Year-wise Trend by Type of Partnership Model Adopted
Table 14.20. Recent Partnerships: Distribution by Type of Therapy
Table 14.21. Recent Partnerships: Distribution by Type of Therapy and Type of Partnership Model Adopted
Table 14.22. Recent Partnerships: Distribution by Cell Processing Step
Table 14.23. Recent Partnerships: Distribution by Automated and Closed Cell Processing System
Table 14.24. Recent Partnerships: Distribution by Type of Partner
Table 14.25. Recent Partnerships: Distribution by Type of Cell Processing Step and Developer
Table 14.26. Recent Partnerships: Most Active Players
Table 14.27. Recent Partnerships: Country-Wise Distribution
Table 14.28. Recent Partnerships: Intercontinental and Intracontinental Distribution
Table 14.29. Big Pharma Initiatives Summary
Table 14.30. Cost Saving Analysis: Comparative Analysis of Manual, Partially Automated and Fully Automated Processing Systems, 2020-2030
Table 14.31. Cost Saving Potential of Fully Automated Processing Systems Based on Number of Patients
Table 14.32. Cost Saving Potential of Fully Automated Processing Systems Across Different Regions
Table 14.33. Overall Automated and Closed Cell Therapy Processing Systems Market, 2020-2030 (USD Million)
Table 14.34. Automated and Closed Cell Therapy Processing Systems Market: Distribution by Cell Therapy Processing Step, 2020, 2025 and 2030 (USD Million)
Table 14.35. Automated and Closed Cell Therapy Processing Systems Market: Share of Cell Apheresis Systems, 2020-2030 (USD Million)
Table 14.36. Automated and Closed Cell Therapy Processing Systems Market: Share of Cell Separation Systems, 2020-2030 (USD Million)
Table 14.37. Automated and Closed Cell Therapy Processing Systems Market: Share of Cell Expansion Systems, 2020-2030 (USD Million)
Table 14.38. Automated and Closed Cell Therapy Processing Systems Market: Share of Cell Harvesting Systems, 2020-2030 (USD Million)
Table 14.39. Automated and Closed Cell Therapy Processing Systems Market: Share of Fill Finish Systems, 2020-2030 (USD Million)
Table 14.40. Automated and Closed Cell Therapy Processing Systems Market: Share of Cryopreservation Systems, 2020-2030 (USD Million)
Table 14.41. Automated and Closed Cell Therapy Processing Systems Market: Share of Thawing Systems, 2020-2030 (USD Million)
Table 14.42. Automated and Closed Cell Therapy Processing Systems Market: Distribution by Scale of Operation, 2020, 2025 and 2030 (USD Million)
Table 14.43. Automated and Closed Cell Therapy Processing Systems Market: Share of Preclinical / Clinical Scale Operations, 2020-2030 (USD Million)
Table 14.44. Automated and Closed Cell Therapy Processing Systems Market: Share of Commercial Operations, 2020-2030 (USD Million)
Table 14.45. Automated and Closed Cell Therapy Processing Systems Market: Distribution by End User, 2020, 2025 and 2030 (USD Million)
Table 14.46. Automated and Closed Cell Therapy Processing Systems Market: Share of Hospitals / Medical Centers / Clinics / Research Institutes / Academic Institutes, 2020-2030 (USD Million)
Table 14.47. Automated and Closed Cell Therapy Processing Systems Market: Share of Commercial Organizations, 2020-2030 (USD Million)
Table 14.48. Automated and Closed Cell Therapy Processing Systems Market: Distribution by Key Geographical Regions, 2020, 2025 and 2030 (USD Million)
Table 14.49. Automated and Closed Cell Therapy Processing Systems Market: Share of North America, 2020-2030 (USD Million)
Table 14.50. Automated and Closed Cell Therapy Processing Systems Market: Share of Europe, 2020-2030 (USD Million)
Table 14.51. Automated and Closed Cell Therapy Processing Systems Market: Share of Asia-Pacific, 2020-2030 (USD Million)
Table 14.52. Automated and Closed Cell Therapy Processing Systems Market: Share of LATAM, 2020-2030 (USD Million)
Table 14.53. Automated and Closed Cell Therapy Processing Systems Market: Share of MENA, 2020-2030 (USD Million)

List of Companies

The following companies / institutes / government bodies and organizations have been mentioned in the report.

1. 3P Biopharmaceuticals
2. A*STAR's Institute of Molecular and Cell Biology
3. AbbVie
4. Accellix
5. Acer Therapeutics
6. Achilles Therapeutics
7. Activartis Biotech
8. Adaptimmune
9. Adicet Bio
10. Aduro Biotech
11. Adva Biotechnology
12. Advent Bioservices 
13. AgenTus Therapeutics
14. Aglaris
15. AK (Suzhou) Biomedical
16. Aldagen
17. Allele Biotechnology & Pharmaceuticals
18. Allergan
19. Allife Medical Science and Technology
20. Allogene Therapeutics
21. Altor BioScience
22. AmerCare
23. Amgen
24. Amphera
25. Anhui Kedgene Biotechnology
26. ANI Pharmaceuticals
27. Anterogen
28. apceth Biopharma
29. Araymondlife
30. ARBELE
31. Argos Therapeutics
32. Asahi Glass Company
33. Aseptic Technologies
34. Astellas Pharma
35. Asterias Biotherapeutics
36. Astraveus
37. AstraZeneca
38. Asymptote
39. Atara Biotherapeutics
40. Athersys
41. Atlantic Bio GMP
42. ATLATL Innovation Cluster
43. Atreca
44. Aurora Biopharma
45. Autolus
46. AVAX Technologies
47. Basic Pharma
48. Batavia Bioservices
49. Bavarian Nordic
50. Baxalta
51. Baxter
52. Bayer
53. Beijing Biohealthcare Biotechnology
54. Beijing Doing Biomedical
55. Beijing Immunochina Medical Science & Technology
56. Beijing Sanwater Biological Technology
57. Beijing Tricision Biotherapeutics 
58. Beike Biotechnology
59. Bellicum Pharmaceuticals
60. Bio Elpida
61. BioAtla
62. BioCardia
63. Biogen
64. Bioinova
65. BioNTech Innovative Manufacturing Services
66. Bio-Process Systems Alliance
67. BioRestorative Therapies
68. Biosafe
69. Biotec Services International
70. Bio-Techne
71. bluebird bio
72. Boehringer Ingelheim
73. Bone Therapeutics
74. BrainStorm Cell Therapeutics
75. Brammer Bio
76. Bristol Myers Squibb
77. BTI
78. Caladrius Biosciences
79. CANCER-ID
80. Capricor Therapeutics
81. Captain T Cell
82. CardioCell
83. Carina Biotech
84. CARsgen Therapeutics
85. CAR-T (Shanghai) Biotechnology
86. Cartherics
87. Celgene
88. Celixir
89. Cell and Gene Therapy Catapult
90. Cell Biotech
91. Cell Genesys
92. Cell Tech Pharmed
93. Cell Therapies
94. Cellectis
95. CELLforCURE
96. CellGenix
97. Cellin Technologies
98. Cellmed
99. CellPraxis
100. CellProtect Nordic Pharmaceuticals
101. CellProthera
102. Cellular Biomedicine Group
103. Cellular Therapeutics
104. Celularity
105. Celyad
106. Centre for Commercialization of Regenerative Medicine
107. Chengdu MedGenCell
108. CiMaas
109. Cognate BioServices
110. Cook MyoSite
111. Cord Blood Registry
112. Cordlife
113. Corestem
114. CRISPR Therapeutics
115. CRMI
116. Cryosite
117. Cytiva
118. Cytopeutics
119. Cytori Therapeutics
120. Cytosen Therapeutics
121. Cytovac
122. CyTuVax 
123. Daiichi Sankyo
124. Daikyo Seiko
125. Danaher
126. DanDrit Biotech
127. DCPrime
128. Delta-Vir
129. DEMCON
130. Dendreon
131. DiscGenics
132. Draper
133. Eli Lilly
134. Endocyte
135. Esco Aster
136. Esco VacciXcell
137. Eureka Therapeutics
138. Eutilex
139. Ever Union Biotechnology 
140. eXmoor Pharma Concepts
141. EXUMA Biotechnology
142. Fate Therapeutics
143. Ferrer Internacional
144. FIB Hospital Infantil Universitario Niño Jesús
145. Fibrocell Technologies
146. Five Prime Therapeutics
147. Flaskworks
148. FloDesign Sonics
149. Formula Pharmaceuticals
150. Fortress Biotech
151. Fred Hutchinson Cancer Research Center
152. Freeline
153. Fresenius Kabi
154. FUJIFILM Cellular Dynamics
155. FUJIFILM Diosynth Biotechnologies
156. Gadeta
157. Gamida Cell
158. GC Cell
159. G-Con Manufacturing
160. GE Healthcare
161. GE Medical Systems Trade & Development (Shanghai)
162. Genentech
163. Genzyme
164. GigaGen 
165. Gilead Sciences
166. GlaxoSmithKline
167. Global Cell Med
168. Glycostem Therapeutics
169. GPB Scientific
170. Gracell Biotechnologies
171. Gradalis
172. Green Cross
173. GRI Bio
174. Guangzhou Trinomab Biotech
175. Haemonetics
176. Heat Biologics
177. Hebei Senlang Biotechnology
178. Hemostemix
179. HengRui YuanZheng Bio-Technology
180. Histocell
181. Histogenics
182. Hitachi Chemical Advanced Therapeutics Solutions
183. Holostem Terapieavanzate
184. Human Life CORD Japan
185. Hunan Zhaotai Yongren Biotech
186. iCarTAB BioMed
187. iCell Gene Therapeutics
188. Immatics
189. Immune Therapeutics
190. Immunicum
191. ImmunoCellular Therapeutics
192. Immunocore
193. Immunovative Therapies 
194. IncoCell Tianjin
195. Incysus
196. Innovative Cellular Therapeutics
197. Inovio Pharmaceuticals
198. inRegen
199. Intellia Therapeutics
200. Intrexon
201. Invetech
202. Iovance Biotherapeutics
203. ISTO Technologies
204. Ivy Life Sciences
205. Janssen
206. Japan Tissue Engineering (J-TEC)
207. Johns Hopkins University
208. Johnson & Johnson
209. Juno Therapeutics
210. JW Biotechnology
211. JW CreaGene
212. KangStem Biotech
213. Kawasaki Heavy Industries
214. KBI Biopharma
215. Kiromic
216. Kite Pharma
217. Konkuk University
218. kSep Systems
219. Kuur Therapeutics
220. Legend Biotech
221. Leucid Bio
222. Lifecells
223. Lion TCR
224. Living Pharma
225. Longeveron
226. Lonza
227. Lorem Cytori
228. Lorem Vascular
229. Marino Biotechnology
230. Marker Therapeutics
231. MaSTherCell
232. Max Planck Institute for Dynamics of Complex Technical Systems
233. MaxCyte
234. MedCision
235. Medeor Therapeutics
236. Medigene
237. MEDINET
238. MEDIPOST
239. MedVax Technologies
240. Merck
241. Merck Serono
242. Mesoblast
243. MicrofluidX
244. Miltenyi Biotec
245. Minovia Therapeutics
246. MolecuVax
247. MolMed
248. Moraga Biotechnology
249. Multimmune
250. Mustang Bio 
251. NantKwest
252. Neopharm
253. NewLink Genetics
254. Nikon CeLL innovation
255. Nkarta
256. Noga Therapeutics
257. Nohla Therapeutics
258. Noile-Immune Biotech
259. Northern Therapeutics
260. Northwest Biotherapeutics
261. Novadip Biosciences
262. Novartis
263. NovaRx
264. Novella Clinical
265. Novo Nordisk
266. Octane Biotech
267. OhioHealth
268. OiDE BetaRevive
269. Ompi
270. Oncobiomed
271. Opexa Therapeutics
272. Orchard Therapeutics
273. Orgenesis
274. Ori Biotech
275. Osiris Therapeutics
276. OSPIN
277. Oxford BioMedica
278. Oxford MEStar
279. Pall Corporation
280. Parker Institute for Cancer Immunotherapy
281. PDC*line Pharma
282. PersonGen BioTherapeutics
283. Pfizer
284. PharmaBio
285. PharmaCell
286. Pharmicell
287. Pinze Lifetechnology
288. Pique Therapeutics
289. Pluristem Therapeutics
290. Poseida Therapeutics
291. Praxis Pharmaceutical
292. Precision BioSciences
293. Pregene ShenZhen Biotechnology
294. Immutep
295. Promethera Biosciences
296. Regeneris Medical
297. Regeneron
298. Regeneus
299. ReNeuron
300. RHEACELL
301. Roche
302. Roslin Cells
303. Sangamo Therapeutics
304. Sanofi
305. Saronic Biotechnology
306. Sartorius
307. Sartorius Stedim Biotech
308. SCHOTT
309. Scinogy
310. Scinus Cell Expansion
311. Sclnow Biotechnology
312. Seattle Genetics
313. Seneca Biopharma
314. Sentien Biotechnologies
315. Servier
316. Shanghai Bioray Laboratory
317. Shanghai GeneChem
318. Shanghai Houchao Biotechnology
319. Shanghai iCELL Biotechnology
320. Shanghai Longyao Biotechnology
321. Shanghai Unicar-Therapy Bio-medicine Technology
322. Sheba Medical Center
323. Shenzhen BinDeBio
324. Shenzhen Hornetcorn Biotechnology
325. Shibuya
326. Shionogi
327. Shreedhar Instruments
328. Singota Solutions
329. Sinobioway Cell Therapy
330. SMT Bio
331. Sorrento Therapeutics
332. SOTIO
333. Southwest Research Institute
334. SQZ Biotech
335. Stafa Cellular Therapy
336. Stanford School of Medicine
337. Stem Cell Arabia
338. STEMCELL Technologies
339. Stemedica Cell Technologies
340. Stempeutics Research
341. Super-T Cell Cancer Company
342. Surface Oncology
343. Tactiva Therapeutics
344. Taiwan Bio Therapeutics
345. Takara Bio
346. Takeda Pharmaceuticals
347. TapImmune 
348. Targazyme
349. TC BioPharm
350. TCR2 Therapeutics
351. Tella
352. Terumo BCT
353. Tessa Therapeutics
354. Teva Pharmaceutical Industries
355. TheraCell Advanced Biotechnology
356. Thermo Fisher Scientific
357. ThermoGenesis
358. Tianhe Stem Cell Biotechnologies
359. TiGenix
360. TILT Biotherapeutics
361. Tissue Genesis
362. Tmunity Therapeutics
363. TNK Therapeutics
364. TotipotentRX
365. TRACT Therapeutics
366. TrakCel
367. TransCure BioServices
368. Triumvira Immunologics
369. TVAX Biomedical
370. Shanghai Unicar Therapy Bio medicine Technology
371. Universal Cells
372. University of California, Davis
373. University Of North Carolina Lineberger Comprehensive Cancer Center
374. Unum Therapeutics
375. US Stem Cell
376. Vaccinogen
377. Vanrx Pharmasystems
378. Vericel
379. ViroMed
380. Viscofan BioEngineering
381. VivaBioCell
382. Volta Therapeutics
383. Waisman Biomanufacturing
384. WiSP Wissenschaftlicher Service Pharma
385. Wuhan Sian Medical Technology
386. WuXi AppTec
387. Xcelthera
388. Xellbiogene
389. XEME Biopharma
390. Yposkesi
391. Zelluna Immunotherapy 
392. Zenith Technologies
393. Zimmer Biomet
394. Ziopharm Oncology